175357-98-9

Basic information

• Product Name: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE
• Synonyms: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE;Pyrido[3,4-d]pyriMidine,4-chloro-6-fluoro-
• CAS NO: 175357-98-9
• Molecular Formula: C₇H₃ClFN₃
• Molecular Weight: 183.5702232
• Product Categories: CHIRAL CHEMICALS
• Mol File: 175357-98-9.mol

Chemical Properties

• Boiling Point: 331.65 °C at 760 mmHg
• Flash Point: 154.377 °C
• Appearance: /
• Density: 1.537±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.645
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.82±0.30(Predicted)
• CAS DataBase Reference: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE(175357-98-9)
• EPA Substance Registry System: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE(175357-98-9)

Safety Data

• Hazardous Substances Data: 175357-98-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and halogenated nature may contribute to the development of new drugs with specific therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE is used as a building block for the design and synthesis of novel bioactive molecules. Its presence in a molecule can potentially influence the pharmacokinetic and pharmacodynamic properties of the resulting compounds, making it a valuable tool for drug discovery.
Used in Chemical Synthesis:
4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE is used as a reactant in various chemical synthesis processes. Its reactivity and functional groups can be exploited to form new compounds with diverse applications in different industries.
Used in Material Science:
In material science, 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE may be used as a component in the development of new materials with specific properties. Its incorporation into polymers, for example, could lead to materials with improved stability, conductivity, or other desirable characteristics.

InChI:InChI=1/C7H3ClFN3/c8-7-4-1-6(9)10-2-5(4)11-3-12-7/h1-3H

Upstream product

• 171178-44-2 6-fluoro-4-oxo-3H-pyrido[3,4-d]pyrimidine 
• 68-12-2 N,N-dimethyl-formamide 
• 171178-43-1 5-Amino-2-fluoropyridine-4-carboxylic acid 
• 171178-41-9 (6-fluoro-pyridin-3-yl)-carbamic acid, tert-butyl ester 
• 1827-27-6 2-fluoro-5-aminopyridine 
• 171178-42-0 5-[N-(tert-Butoxycarbonyl)-amino]-2-fluoropyridine-4-carboxylic acid 

Downstream Products

• 171179-03-6 4-[(3-bromophenyl)-amino]-6-fluoropyrido[3,4-d]pyrimidine 
• 194024-42-5 4-[(3-Chlorophenyl)amino]-6-fluoropyrido[3,4-d]-pyrimidine 
• 194024-40-3 6-Fluoro-4-[(3-methylphenyl)amino]pyrido[3,4-d]-pyrimidine 
• 196796-55-1 4-<(3-chloro-4-fluorophenyl)amino>-6-fluoropyrido<3,4-d>pyrimidine 
• 845522-39-6 cyclohexyl-(6-fluoro-pyrido[3,4-d]pyrimidin-4-yl)-amine 
• 845522-46-5 (6-Fluoro-pyrido[3,4-d]pyrimidin-4-yl)-(trans-4-methyl-cyclohexyl)-amine 
• 855995-81-2 4-[2-(6-fluoro-pyrido[3,4-d] pyrimidin-4-ylamino)-phenoxy]-butyric acid ethyl ester 
• 2135696-72-7 (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide 
• 799242-60-7 4-[4-(6-fluoro-pyrido[3,4-d]pyrimidin-4-ylamino)-2-methyl-phenoxy]-benzoic acid tert-butyl ester 
• 799242-56-1 3-[4-(6-fluoro-pyrido[3,4-d]pyrimidin-4-ylamino)-2-methyl-phenoxy]-benzoic acid tert-butyl ester 
• 194024-44-7 6-Fluoro-4-[[(3-trifluoromethyl)phenyl]amino]-pyrido [3,4-d]pyrimidine 
• 194024-36-7 6-fluoro-4-(phenylamino)pyrido<3,4-d>pyrimidine 

Relevant articles and documents

USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS

Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti- HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti -HER2/HER3 antibodies.

HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS

Provided are cyclic iminopyridimdine compounds and their bicyclic derivatives, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to B-Raf V600E kinase.

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family

Structure-activity relationships for inhibition of erbB1, erbB2, and erbB4 were determined for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogues of the irreversible pan-erbB inhibitor, canertinib. Cyclic amine bearing crotonamides were determined to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays. The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated. Several anilines were identified as providing potent, reversible pan-erbB inhibition. Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo. Quinazoline 54 and pyrido[3,4-d]pyrimidine 71 were identified as clearly superior to canertinib. Both compounds possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents, respectively. Pharmacokinetic comparison of compounds 54 and 71 across three species selected compound 54 as the preferred candidate. Compound 54 (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clinical evaluation.

PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY

The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.

The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer

The synthesis and biological evaluation of potent and selective inhibitors of the erbB2 kinase is presented. Based on the 4-anilinoquinazoline chemotype, the syntheses of several new series of erbB2 inhibitors are described with quinazoline and pyrido[4,3

Microwave-assisted synthesis of mGluR1 ligands: carbon, nitrogen and oxygen linked derivatives of pyrido[3,4-d]pyrimidin-4-ylamines

The syntheses of 6-fluoropyrido[3,4-d]pyrimidin-4-ylamine derivatives is reported herein. Methods for generating C, N and O linked analogues under microwave irradiation are described.

PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI- PROLIFERATIVE AGENTS

The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein a1-a2=a3-a4represents a d

Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 3. Replacement of Quinazoline Moiety and Improvement of Metabolic Polymorphism of 4-[4-(N-Substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline Derivatives

We have previously reported that a series of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives were potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation and demonstrated several biological effects such as suppression of neointima formation following balloon injury in rat carotid artery by oral administration. Here, we investigated structure-activity relationships of the 6,7-dimethoxyquinazolinyl moiety. In regard to 6,7-dimethoxy groups, ethoxy analogues showed potent activity (IC50 of 16b is 0.04 μM; IC50 of 17a is 0.01 μM) and further extension of the alkyl group reduced activity. Interestingly, methoxyethoxy (IC50 of 16j is 0.02μM; IC50 of 17h is 0.01 μM) and ethoxyethoxy (IC50 of 17j is 0.02 μM) analogues showed the most potent activity, suggesting that the inserted oxygen atom significantly interacts with β-PDGFR. Among tricyclic quinazoline derivatives, the 2-oxoimidazo[4,5-e]quinazoline derivative 21a showed potent activity (IC 50 = 0.10 μM). Regarding replacements of quinazoline by other heterocyclic rings, pyrazolo[3,4-d]pyrimidine (39a, IC50 = 0.17 μM) and quinoline (IC50 of 40a is 0.18 μM; IC50 of 40b is 0.09 μM) derivatives showed potent activity. Isoquinoline and some pyridopyrimidine derivatives were completely inactive; therefore, 1-aza has an important role. Also 7-aza and 8-aza substitution on the parent quinazoline ring has a detrimental effect on the interaction with β-PDGFR. We also demonstrated that the substituents on the quinazoline ring possess major consequences for metabolic polymorphism. Although there existed extensive metabolizers and poor metabolizers in Sprague-Dawley rats administrated 6,7-dimethoxyquinazoline derivatives (1b and 1c), 6-(2-methoxy)ethoxy-7-methoxyquinazoline analogue 16k showed no metabolic polymorphism.